Assessing potential of psilocybin for depressive disorders
Zofia Kozak, Matthew W Johnson, Scott T Aaronson
Expert Opinion on Investigational Drugs October 3, 2023 DOI: 10.1080/13543784.2023.2273493 via OpenAlex
Summary
AI-generated from the abstractPatients with treatment-resistant depression may be the most suitable candidates for psilocybin treatment when weighing known risks and benefits against existing standards of care. Much remains unknown about the risks of psilocybin treatment.
Study at a glance
| Characteristics | Review Peer reviewed |
|---|---|
| Population | Patients with depression, specifically those with treatment-resistant depression |
| Topics | Depression Psychedelic-assisted therapy |
| Keywords | Psilocybin, psychedelics Magic mushroom therapy Treatment-resistant depression trd |
| Citations | 10 |
| Key finding | Patients with treatment-resistant depression may be the most suitable candidates for psilocybin treatment at this time. |
Abstract
There is still much unknown regarding the risks of psilocybin treatment. When weighing the known risks and benefits of psilocybin treatment against those found in existing standards of care, among patients with depression, patients with treatment-resistant depression (TRD) may be the most suitable candidates for psilocybin treatment at this time.